Barzolvolimab is a monoclonal antibody commercialized by Celldex Therapeutics, with a leading Phase I program in Chronic Urticaria Or Hives. According to Globaldata, it is involved in 10 clinical trials, of which 3 were completed, 5 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Barzolvolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Barzolvolimab is expected to reach an annual total of $177 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Barzolvolimab Overview

Barzolvolimab (CDX-0159 is under development for the treatment of chronic idiopathic urticaria (CIU), eosinophilic esophagitis (EoE), prurigo nodularis and unspecified cancer. The drug candidate is a second generation version of CDX-0158 (fragment crystallizable (Fc) portion of CDX-0158 antibody is modified). It acts by targeting tyrosine protein kinase Kit. It is administered through intravenous and subcutaneous route. 

Celldex Therapeutics Overview

Celldex Therapeutics (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Massachusetts, the US, and research laboratories in Massachusetts, New Jersey, and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

The company reported revenues of (US Dollars) US$4.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 37.3% over FY2020. The operating loss of the company was US$71.2 million in FY2021, compared to an operating loss of US$63.4 million in FY2020. The net loss of the company was US$70.5 million in FY2021, compared to a net loss of US$59.8 million in FY2020. The company reported revenues of US$0.4 million for the third quarter ended September 2022, compared to a revenue of US$0.2 million the previous quarter.

For a complete picture of Barzolvolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.